Clinical trial · Observational
Echocardiography for RILI Prediction
The Value of Echocardiography for Prediction of Radiation-induced Lung Injury in Non-small Cell Lung Cancer Patients Treated With Chemoradiation: an Onco-cardiac Prospective Cohort Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study is prematurely terminated due to bad inclusion and the fact that examinations are already being used in standard care.
Summary
Brief summary (as posted)
Severe radiation-induced lung injury (RILI) occurs in approximately 20% of the lung cancer patients, who are treated with curative chemoradiation. In this study the investigators want to evaluate the prognostic value of baseline cardiac function assessed with echocardiography for prediction of RILI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Dyspnea score at three months after (chemo)radiotherapy, assessed by the patient version of the CTCv4.0
- timeFrame
- up to 3 months
Secondary outcomes (17)
- measure
- Dyspnea score at six months after (chemo)radiotherapy, assessed by the patient version of CTCv4.0
- timeFrame
- up to 6 months
- measure
- Changes in dyspnea score after radiotherapy, compared to baseline
- timeFrame
- up to 12 months
- measure
- Change in Left Ventricle Ejection Fraction (LVEF) (baseline versus 3-month after chemo radiation)
- timeFrame
- up to 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical stage I-III non small cell lung cancer, excluding malignant pleural/pericardial effusion * Planned for curatively intended primary (chemo)radiotherapy, due to irresectable disease and/or medical inoperability * WHO performance status 0-2 * No history of prior chest radiotherapy * No uncontrolled infectious disease * No other active malignancy * No prior lung surgery (VATS, wedge resection, segment resection, lobectomy) * Willing and able to comply with the study prescriptions * 18 years or older * Ability to give and having given written informed consent before patient registration Exclusion Criteria: * malignant pleural/pericardial effusion * history of prior chest radiotherapy * uncontrolled infectious disease * other active malignancy * prior lung surgery (VATS, wedge resection, segment resection, lobectomy)
References
Publications (0)
Data not yet available